© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Ranolazine didn’t just appear overnight on pharmacy shelves. Researchers looking for better treatment for angina kept stumbling on the same walls with older therapies like beta-blockers and calcium channel blockers. The persistent struggle for a drug that didn’t drop blood pressure, didn’t slow heart rates, and still managed to help folks with chest pain kept the hunt alive through the 1980s and 1990s. Ranolazine found its stride in early trials, helping patients continue their daily routines without having to live under the thumb of side effects. Eventually, after rigorous studies and enough regulatory hurdles to call it a full-blown trek, the FDA approved ranolazine for use in chronic angina — not acute emergencies, but for regular, everyday management. Its unique mechanism set it apart: instead of squeezing blood vessels or slowing the heart, it fiddles with sodium channels, allowing the heart to handle oxygen better. That gave patients more freedom and gave doctors another tool in their kit.
Ranolazine comes packaged as both extended-release tablets and, in some settings, as a raw active pharmaceutical ingredient. Pharmacies everywhere recognize it under the brand name “Ranexa,” but generics run in parallel. Most doses come in 500 mg and 1000 mg formats — intended for easy titration depending on how much relief a patient needs. The drug stays tucked into a sleek blue-and-white tablet with very little in the way of smell or taste, built for daily use. The long-acting formulation keeps medication levels steady, avoiding the rollercoaster ride some older drugs could cause. It turns up in doctors’ offices, community pharmacies, and hospital clinics, stored in basic room temperature conditions, and doesn’t ask for anything fancy in terms of reconstitution or refrigeration.
At a glance, ranolazine doesn’t make a big visual impression. White, crystalline – the type of powder that blends into the scenery in a compounding pharmacy. Chemically, it stacks up as C24H33N3O4, with a molecular weight around 427.54 g/mol. It melts in the ballpark of 122-123°C, dissolving better in organic solvents like methanol than in water (which always keeps chemists on their toes in formulation). The compound remains stable under standard conditions, which makes it much easier for distribution and shelf storage, a real bonus from a logistical standpoint. Tablets take advantage of its low aqueous solubility by stretching out the release profile, making the most of each dose.
Every box, bottle, or strip of ranolazine spells out strength, expiration date, and batch number, meeting strict labeling demands. The U.S. Pharmacopeia lays down purity specifications: usually a minimum of 98.5% pure by HPLC, with specified limits for related substances. Moisture content, residue on ignition, particle size — all these technical bits get checked during QC. Labels must warn users about possible interactions, especially with CYP3A inhibitors or inducers, as these can hike up ranolazine exposure or wipe it out too fast. Tablets list inactive ingredients, storage instructions, and directions for splitting doses, if needed. All these measures help keep patients and healthcare professionals on the same page.
The story of ranolazine’s manufacture starts with the synthesis of its central piperazine ring, a structure at the core of its function. Organic chemists join methylphenoxy-acetate and a suitably protected aminopyridine, typically through nucleophilic substitution and amidation steps, to slowly build up complexity. Once the key building blocks snap together, multiple steps involving alkylation and cyclization lock the structure into its final active form. The process demands careful purification, often by column chromatography or recrystallization, to meet pharma-grade purity. Large manufacturers scale up the process with specialty reactors, taking special care about waste streams—since environmental safety matters just as much as the chemistry itself.
Ranolazine’s core doesn’t change much in final form, but along the way, plenty of chemical shuffling happens. Chemists rely on stable intermediates that handle substitutions on the aromatic rings, giving the molecule its pharmacological kick. Key reactions utilize controlled alkylation to attach bulky side groups, expanding the molecule’s functionality. Each lab tweak aims to improve bioavailability, tinker with release profiles, or limit impurities. Research teams occasionally swap out functional groups or try prodrug strategies, chasing even better absorption or fewer side effects. Even small modifications on the molecule’s “tail” — such as halogenation or esterification — have led to related structures that keep popping up in cardiovascular pipelines.
Ranolazine stands out in pharmacy software as its generic name, yet it picks up plenty of aliases on the street: “Ranexa,” its biggest brand in the U.S., along with generic listings as “Ranozex” or local branded names across various countries. Chemists point to its IUPAC name, N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide, which rarely makes it onto doctor’s pads. Some research catalogs log it by CAS number 95635-55-5 for precision. No matter the change in label, hospitals, and pharmacists turn to it for chronic angina support.
Pharmacies treat ranolazine with the usual set of good manufacturing practices. People mixing, pressing, and bottling it wear gloves and limit dust exposure. The main risk isn’t acute toxicity, but long-term handling without basic PPE could build up irritation. Tablets and powders don’t show much volatility or fire hazard, so most facilities don’t keep it locked in chemical safety cabinets. On the patient side, healthcare providers watch for QT prolongation in vulnerable populations, especially people already on other medications tipping the cardiac balance. Automated reminders flag these interactions during prescribing and dispensing, keeping everyone one step ahead.
Practically every cardiology clinic keeps ranolazine in regular rotation for patients who just can’t tolerate standard angina drugs or who need help keeping chest pain managed during daily activities. It’s not designed for sudden relief — no rescue therapy here — so professionals use it for chronic support, letting people walk farther and do more without wheezing or pain. Doctors sometimes blend it with beta-blockers or amlodipine for folks who need all hands on deck. Some ongoing work tries ranolazine in diabetes and arrhythmia, since its sodium channel action may benefit tricky cases beyond angina.
Ranolazine’s story hasn’t ended just because it passed regulatory gates. Research teams keep digging into its off-label uses: from diabetic complications to heart rhythm stabilization. Animal trials and small patient studies show some promise in reducing arrhythmias, especially ventricular tachycardia, sparking new clinical trials in atrial fibrillation. Other studies dig into possible roles in metabolic syndrome, spurred by its minor impact on blood glucose and HbA1c. Synthetic chemists continue to explore tweaks on the basic structure, hunting for versions of the molecule that punch even harder or dodge some of the minor side effects reported with current use. Pharma companies pour resources into extended-release or even once-weekly versions, hoping to tip the adherence scales in chronic disease management.
Toxicologists took no shortcuts before ranolazine made it to the market. Preclinical trials cross-checked liver, kidney, and cardiovascular effects at doses far higher than those used in humans. In animals, massive overdoses sometimes caused tremors and motor restlessness, but the drug washed out rapidly. Human studies reported occasional dizziness, nausea, and some constipation, but drug-induced QTc prolongation grabbed the most attention. Doctors and regulators flagged it for close ECG monitoring, especially in people with pre-existing long QT or those on other QT-prolonging drugs. No evidence of carcinogenicity or mutagenicity has surfaced in formal studies, yet pharmacovigilance still asks for regular reporting of any unexpected reactions.
Looking forward, the push sits squarely on expanding ranolazine’s therapeutic range. Upcoming clinical trials chase answers in diabetic neuropathy, microvascular angina, and chronic arrhythmias. Meanwhile, scientists probe long-term outcomes hoping to prove ranolazine can not just manage symptoms but shift the natural progression of cardiovascular disease. Innovative drug delivery platforms — think patches, depot injections, or nanoparticle suspensions — may soon hit the drawing board, taking the pressure off rigid dosing schedules. Hospital formularies increasingly accept ranolazine, opening doors for global access, especially in regions dealing with rising rates of heart disease. In my years around community clinics and research networks, patients who finally find relief with ranolazine tend to stick with it, telling stories of rediscovered independence. New data and tech developments could keep ranolazine’s story growing, helping it remain a steady option for angina and potentially much more in tomorrow’s world of medicine.
When my uncle faced a bout of persistent chest pain, or what his doctor called angina, his prescription bag looked like a pharmacy in miniature form. He tried everything from nitroglycerin tablets to beta blockers, but his episodes kept returning. That’s how he ended up with a new medicine: ranolazine. I watched closely because, in my family and many others, heart disease holds a heavy shadow. Understanding why he needed this new drug felt important, not only for his well-being but for anyone riding the same turbulent journey with chronic heart issues.
Cardiologists recommend ranolazine to fight a specific foe: chronic angina that doesn’t quit, even after the usual suspects are on board. These are the people who keep getting chest pain despite standard therapy. Standard options, like nitrates or blockers, either relax blood vessels or slow the heart. Ranolazine takes another approach. Rather than affecting heart rate or blood pressure, it works inside heart cells, targeting the sodium channels that turn unstable when oxygen drops off. Less sodium means less calcium entering the cells, which means the heart muscle isn't squeezed as hard. That results in fewer or milder chest pains for many folks.
Studies back this up. A major trial, known as MARISA (Monotherapy Assessment of Ranolazine In Stable Angina), showed patients on ranolazine carried out more exertion with fewer painful interruptions. Another well-respected study, CARISA (Combination Assessment of Ranolazine In Stable Angina), found it also helps when used with other regular heart meds. That combination gave patients the liberty to walk farther or climb more stairs before angina appeared. These improvements make day-to-day life feel less like an obstacle course.
My uncle’s relief from chest pain was real, but so were the conversations about side effects. Ranolazine sometimes brings dizziness or stomach upset. In rare cases, it can shake up the ECG with changes that doctors need to monitor. It doesn’t replace tried-and-true medications. The most impact shows in people already juggling two or more other angina drugs without success. Any new medicine, particularly one affecting the heart, demands respect and close follow-up. That’s true whether you’re just starting ranolazine or have been taking it for years.
Generic versions of ranolazine have dropped the price somewhat, though it still runs higher than older meds. Insurance coverage varies. That reality leaves some patients stuck deciding between better relief and higher costs. Out-of-pocket costs influence patient adherence, which can mean people either don’t fill their prescriptions or cut pills in half to make them last. Open communication with doctors and insurance providers plays a big part in these situations, ensuring patients don’t fall through the cracks for lack of clear information or support.
The world of heart medications keeps changing, and so does the landscape of angina treatment. Reliable information, plain talk with medical teams, and ongoing research keep everyone moving in the right direction. My uncle’s experience tells me that for those who haven’t found relief with other options, ranolazine offers a real shot at a fuller, less restricted life. It stands as one more way to keep hearts—and people—moving forward.
People living with chronic angina—the type where chest pain keeps coming back—sometimes sit across from a doctor and hear the name “Ranolazine.” This medicine helps folks find relief when older drugs don’t cut it, making daily walks or trips to the grocery store a little more manageable. As with any medication, comfort and caution travel together. Nobody wants to swap one kind of suffering for another. That’s why looking at the most common side effects matters.
Many who take ranolazine notice some changes soon after starting. Nausea shows up on plenty of lists—nearly 5% of people using this drug feel queasy. Dizziness follows close behind. Sitting up too quickly or standing after a meal can trigger lightheadedness, and on bad days it feels hard to trust your own body. A handful of users mention headaches that arrive without warning. Constipation also lingers as a complaint, especially for those juggling several medications at once.
Sometimes the heart itself acts up, especially if other heart meds or rhythm problems come into play. Palpitations, or fluttering sensations in the chest, tend to get noticed and talked about. Less often, there’s a lengthening of the heart’s QT interval—which doctors track on an EKG. For most healthy people the risk stays low, but anyone with a tangled history of heart rhythm trouble or certain family backgrounds deserves extra eyes on their charts.
Researchers dug through data from over 1,000 patients to get a clearer sense of what to expect. In study after study, side effects seemed dose-dependent: higher doses brought more nuisances, although most effects stayed mild to moderate. Put simply, higher numbers on the pill usually meant more aches and complaints. Still, over 75% of folks stuck with treatment and didn’t need to stop. That says something about the balance of benefit and risk.
Newer research highlights a few rarer problems that feel unsettling if they pop up—things like shortness of breath or swelling in the legs. This can hint at fluid retention or the heart having a hard time. A watchful physician pays attention to these changes. I’ve heard stories in the waiting room about dry mouth, ringing in the ears, and blurry vision, too. Less common, but worth mentioning for anyone who likes to be prepared.
Every person brings their own story: some have kidneys that don’t clear drugs quickly, others take medications that mix poorly with ranolazine. Grapefruit juice, for example, can push levels too high. After talking with pharmacists, I’ve learned how important it is to mention every single pill, supplement, or herbal tea. Checking in regularly with a prescriber can help catch creeping side effects before they spiral.
Simple steps go a long way. Calling out dizziness during routine visits, asking questions if headaches start to take over, or noting subtle swelling in ankles can help catch trouble early. For most, ranolazine fits into life without too much drama, but attention to these signals matters. Better to speak up than suffer in silence.
Doctors prescribe ranolazine for folks who deal with chronic angina, the kind of chest pain that creeps in when the heart muscle doesn’t get enough oxygen. This isn’t a quick-fix pill for heart attacks. Instead, it works more like a steady hand, helping you manage chest tightness and move through your day with less discomfort. Most of us want to trust our medicine cabinet, but understanding why each pill matters makes a real difference. You get closer to real improvement when you know what you’re putting in your body and what you should expect.
Doctors often tell patients to swallow ranolazine tablets twice a day, once in the morning and once in the evening. Chewing or crushing these tablets might feel harmless but it hurts the way the medicine works. They’re designed to release slowly, so breaking them throws off the timing and can raise the chance of side effects.
Try to take your dose with the same meals every day. Food doesn't push ranolazine to dangerous highs or lows, but linking pills to breakfast or dinner helps build a solid routine. Setting a phone alarm or keeping your tablets by your toothbrush helps you avoid missing doses. Staying steady with your schedule keeps chest pain from sneaking up on you.
Sometimes people pick up prescriptions from different doctors or try various over-the-counter treatments. Ranolazine doesn't always play nice with everything. Grapefruit juice and certain antibiotics or antifungals can interfere and change how much medicine ends up in your system. If you use medications for seizures, depression, or heart rhythm, always double-check with your doctor or pharmacist before mixing things up.
Many of us would rather tough things out than call the clinic, but keeping your provider in the loop speeds up solutions if you notice strange side effects or your chest pain returns. Fast or pounding heartbeat, dizziness, feeling faint, or swollen legs need attention—these signs should never be ignored.
Living with angina can force you to make unwelcome compromises, bowing out of walks, family events, or even shopping trips. Medicines like ranolazine open doors many of us thought were shut. My experience watching family faces light up on walks after months on the sidelines reminds me how these steps—big or small—become life's heartbeat. Medicine becomes a small piece of hope, not just another item on a prescription print-out.
Coverage and costs sometimes get in the way. Insurance plans don’t always include the same options. If ranolazine feels too expensive, talk openly with your doctor or pharmacist about generics or alternatives—they know the ropes better than anyone. Nobody should pay the price for simply wanting to breathe easy.
No medicine works in a vacuum. Keeping track of exercise, sleep, and blood pressure multiplies your chances of a healthier life. Carry a small notebook, keep an app updated, or just tell someone you trust how things are going week to week. That helps catch trouble early and reminds you that good health never rests on one pill alone.
Side effects, tricky interactions, or missed doses don’t have to control the story. Honest conversations and small daily choices protect your health more than any single step. Decisions made with the best information—tested by lived experience and backed by real science—help us get back to living instead of just managing symptoms.
Looking at my own family’s battle with heart disease over the years, nobody gets away with a simple prescription. There’s always a handful of bottles, each working on a piece of the puzzle. Ranolazine comes up more and more in those lists, making folks wonder if it really gets along with the heavy hitters like beta blockers, nitrates, or statins. A lot rides on mixing the right meds; getting it wrong means risking real damage, not just some blurred line in a textbook.
Ranolazine targets angina—the chest pain that turns sunlight and steps into chores. Traditional drugs slow the heart or drop blood pressure. Ranolazine takes a different angle, tinkering with sodium channels in the heart. Results can ease pain when old standbys fall short. Cardiologists will often turn to it when other tactics aren’t enough, especially for folks still struggling despite standard treatments.
Anyone who has sorted out a weekly pillbox knows the stakes. Ranolazine can work safely with a host of other heart medicines, but not without limits. ACE inhibitors, ARBs, and basic aspirin usually mix without drama. But dig a bit deeper, and things take a sharp turn.
Ranolazine gets processed by the liver—specifically, cytochrome P450 enzymes, like CYP3A4. Other meds, and even supplements or grapefruit juice, can mess with those same enzymes. If a person already takes diltiazem or verapamil, both common heart drugs, the body might keep more ranolazine around than the prescription intends, setting the stage for side effects. As someone who’s watched a loved one faint from low blood pressure, it’s easy to lose sleep over these unseen battles. Combining ranolazine with certain antiarrhythmics, like quinidine, piles on risk by stretching out the heart’s QT interval, which may trigger dangerous rhythms.
A lot of folks trust their doctors to catch every interaction, but mistakes sneak past the best of intentions. Polypharmacy, especially in older adults, means side effects pile up. Fatigue, dizziness, and changes in heart rhythm don’t always come from the latest prescription—they’re signs that combinations aren’t playing nice.
Recent studies spotlight the need for regular ECGs in these situations. Ranolazine’s unique way of action means its benefits for angina can outweigh risks, as long as doctors keep an eye on the patient’s entire list. That list should include every over-the-counter pill, herbal supplement, and even drinks like grapefruit juice that most folks forget to mention.
Getting the right mix starts at the pharmacy counter. Pharmacists these days catch more interactions than ever, but communication gaps remain. A friend of mine nearly doubled his risk by getting a new prescription from a clinic that missed half the list from another doctor. Shared records would have averted it. People being open and honest about everything they take—without feeling embarrassed—has saved lives.
Regular check-ins, clear record-sharing, and plainspoken conversations are the frontline for safety. One-size-fits-all doesn’t work here; careful adjustment makes room for both symptom relief and peace of mind. For anyone living with a chronic heart condition, that balance gives real hope instead of more anxiety each time a pill gets added to the lineup.
Ranolazine helps people with chronic angina get through their days with a little less pain in their chest. Probably, some folks rely on it to get back to long walks, weekend gardening, or playing with their grandkids. It doesn’t cure heart disease but it can help manage chest pain when other medicines fall short.
Certain health issues create bigger problems with this drug. If someone has serious liver disease cirrhosis, the body can’t clear ranolazine fast enough. The medicine builds up, raising the chance of dizziness, fainting, and even scary heart rhythms. A doctor once explained how the liver acts as a filter, and if that filter is clogged or weak, drugs like this become dangerous. For folks with moderate or severe liver problems, doctors generally keep ranolazine off the table.
Anyone with advanced kidney disease might experience similar problems. The kidneys help clear out meds, too. Patients on dialysis or with severe kidney issues can see ranolazine levels increase, making side effects more likely. Extra caution matters here, as older adults might not always realize their kidneys have slowed down until test results make it clear.
Some people live with long QT syndrome, a rare heart condition. Using ranolazine in this group could trigger dangerous heartbeats or palpitations. The FDA flagged this risk because ranolazine itself can lengthen the QT interval. Heart specialists, who track patients with ECGs, usually steer clear of ranolazine if QT interval issues show up.
Saying “tell your doctor all the medicines you take” isn’t just good advice—it’s essential with ranolazine. Some drugs block or boost the enzymes that process ranolazine. Strong CYP3A inhibitors like ketoconazole (for fungal infections) or certain HIV medicines can make ranolazine build up, spiking side effects. Grapefruit juice works the same way; it can push ranolazine to unsafe levels. On the flip side, CYP3A inducers like rifampin (used for tuberculosis) sweep ranolazine out too quickly, making it useless.
Some people take drugs like diltiazem or verapamil to control their blood pressure or heart rhythm. These affect ranolazine, so doctors often need to cut the starting dose in half or switch things around entirely. Patients on digoxin, simvastatin (cholesterol medicine), or metformin (for diabetes) might need adjustments if ranolazine joins the mix, as these combinations tend to intensify side effects.
No one truly knows how ranolazine affects unborn babies or nursing infants. Women who are pregnant, trying to get pregnant, or breastfeeding should talk through the risks before filling a prescription. The drug hasn’t won approval for children, either. Most experts agree that without enough data on younger patients, saying no to ranolazine is the safe bet for kids and teens.
Filling a prescription never replaces a real conversation. Anyone thinking about ranolazine needs a doctor who looks at their lab tests, their medicine cabinet, and their personal story. Health professionals usually check heart rhythms, liver and kidney numbers, and review every drug or supplement a person takes. People who shop around for one doctor after another or skip follow-ups sometimes miss these vital checks. The best approach involves honesty, up-to-date records, and an open line to medical providers—especially when starting a new medicine like ranolazine.
| Names | |
| Preferred IUPAC name | N-(2,6-dimethylphenyl)-2-(4-morpholin-4-ylbutanoyl)benzamide |
| Other names |
Ranexa Ranolo Ranozex Ranzolont Naztor |
| Pronunciation | /rəˈnəʊ.ləˌziːn/ |
| Identifiers | |
| CAS Number | 95635-55-5 |
| 3D model (JSmol) | `3D model (JSmol)` string for **Ranolazine**: ``` CC1=CC=C(C=C1)C(=O)N(CC)CCOC(C)C2=CC=CC=C2 ``` |
| Beilstein Reference | 2302926 |
| ChEBI | CHEBI:82615 |
| ChEMBL | CHEMBL1201197 |
| ChemSpider | 215658 |
| DrugBank | DB00243 |
| ECHA InfoCard | 100.236.306 |
| EC Number | 2.3.1.243 |
| Gmelin Reference | 107164 |
| KEGG | D08051 |
| MeSH | D053098 |
| PubChem CID | 50913 |
| RTECS number | VG0PS4 |
| UNII | T3K429484W |
| UN number | UN3077 |
| CompTox Dashboard (EPA) | DTXSID4020842 |
| Properties | |
| Chemical formula | C24H33N3O4 |
| Molar mass | 427.544 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.03 g/cm³ |
| Solubility in water | slightly soluble |
| log P | 2.07 |
| Vapor pressure | 1.58E-13 mmHg |
| Acidity (pKa) | pKa = 7.2 |
| Basicity (pKb) | pKb = 7.51 |
| Magnetic susceptibility (χ) | -61.7·10^-6 cm³/mol |
| Refractive index (nD) | 1.544 |
| Dipole moment | 4.68 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 354.8 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -350.9 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -4084 kJ/mol |
| Pharmacology | |
| ATC code | C01EB18 |
| Hazards | |
| Main hazards | May cause dizziness, headache, constipation, nausea; may prolong QT interval leading to serious arrhythmias. |
| GHS labelling | GHS labelling: `"Warning; H319: Causes serious eye irritation."` |
| Pictograms | liver, caution, prescription, tablet |
| Signal word | Warning |
| Hazard statements | Hazard statements: Harmful if swallowed. Causes serious eye irritation. |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. |
| NFPA 704 (fire diamond) | 1-2-0 |
| Flash point | 70°C |
| Autoignition temperature | Autoignition temperature: 410°C (770°F) |
| Lethal dose or concentration | LD50 Mouse (oral): 980 mg/kg |
| LD50 (median dose) | 1,268 mg/kg (rat, oral) |
| PEL (Permissible) | Not established |
| REL (Recommended) | 500 mg twice daily |
| IDLH (Immediate danger) | IDLH: Not listed |
| Related compounds | |
| Related compounds |
Lidocaine Procainamide Mexiletine Phenytoin |
